Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

119.79 +1.35 (+1.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results this Monday after the bell. Here’s what to expect. 
Via StockStory
Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know. 
Via StockStory
Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant... 
Via MarketMinute
Topics Intellectual Property
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for 2026. 
Via Benzinga
Topics Earnings
Earnings Scheduled For October 30, 2025
 
Via Benzinga
Gilead Stock Ignites Retail-Trader Frenzy As Trodelvy Cuts Breast Cancer Progression Risk By 38% In Phase 3 Trial
Via Stocktwits
Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday?
Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap giants kept the rally momentum alive. 
Via Benzinga
Gilead GILD Q3 2025 Earnings Call Transcript
Gilead GILD Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 3% year on year to $7.77 billion. On the other hand, the... 
Via StockStory
Meta Meltdown Sends Nasdaq Tumbling as Apple Shines After Hours
Wall Street slipped on Thursday as disappointing results from Meta and cautious tones from the Fed weighed on sentiment. But after the closing bell, Apple’s record-breaking numbers helped restore a bit... 
Via Chartmill
Topics Economy
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares? 
Via The Motley Fool
Topics Regulatory Compliance
Gilead Sciences Inc (NASDAQ:GILD) Reports Mixed Q3 2025 Results with Strong Earnings Beat and Cautious Revenue Outlook
Gilead Sciences Q3 2025 earnings beat EPS estimates with $2.47, but revenue outlook is cautious. HIV drug Biktarvy drives growth, while Veklury sales decline. 
Via Chartmill
Topics Earnings
Gilead Sciences (NASDAQ:GILD) Exceeds Q3 Expectations
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) announced better-than-expected revenue in Q3 CY2025, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year... 
Via StockStory
Covid Continues To Haunt Gilead. How One Drug Dinged Product Sales.
Excluding the impact of Veklury, Gilead Sciences' product sales would have been closer to analysts' forecast. 
Via Investor's Business Daily
CVS Health Delivers Confident Outlook After Q3 Performance, Stock Hits 52-Week High
CVS Health topped Q3 estimates with $102.9 billion in revenue and raised its 2025 EPS outlook to up to $6.65 amid strong segment growth. 
Via Benzinga
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday?
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome... 
Via Benzinga
Topics Economy
A Glimpse of Gilead Sciences's Earnings Potential
 
Via Benzinga
Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results this Thursday after market close. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
Market's Perilous Peak: Is the U.S. Stock Market More Overvalued Than Ever?
New York, NY – October 27, 2025 – A chorus of concern is growing louder across financial markets, with prominent voices like MarketWatch raising alarm bells over what they describe as an unprecedented... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
 
Via Benzinga
Retail Investors' Top Stocks With Earnings This Week: SoFi, Apple, Meta And More
Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites. 
Via Benzinga
3 Value Stocks We Approach with Caution
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Uncover the latest developments among S&P500 stocks in today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday. 
Via Chartmill
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment
NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to daily oral medication. 
Via Benzinga
Which S&P500 stocks are moving on Friday?
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market... 
Via MarketMinute
Topics Retirement
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 studies with stable weight outcomes. 
Via Benzinga
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months
Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.